DI NUNNO, VINCENZO
 Distribuzione geografica
Continente #
AS - Asia 2.641
NA - Nord America 2.359
EU - Europa 1.281
AF - Africa 208
SA - Sud America 160
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.655
Nazione #
US - Stati Uniti d'America 2.326
SG - Singapore 802
VN - Vietnam 707
CN - Cina 608
IT - Italia 218
GB - Regno Unito 195
SE - Svezia 178
HK - Hong Kong 174
DE - Germania 146
BR - Brasile 104
FR - Francia 90
NL - Olanda 90
SC - Seychelles 86
RU - Federazione Russa 83
KR - Corea 76
IN - India 74
IE - Irlanda 72
CH - Svizzera 56
JP - Giappone 51
FI - Finlandia 48
CI - Costa d'Avorio 46
ZA - Sudafrica 29
TG - Togo 28
AR - Argentina 25
ID - Indonesia 23
PH - Filippine 21
BD - Bangladesh 20
BG - Bulgaria 17
BE - Belgio 15
MX - Messico 15
TH - Thailandia 15
CA - Canada 14
AT - Austria 13
EE - Estonia 12
JO - Giordania 11
PL - Polonia 11
UA - Ucraina 11
TR - Turchia 9
TW - Taiwan 9
EC - Ecuador 8
PK - Pakistan 8
MY - Malesia 7
UZ - Uzbekistan 7
ES - Italia 6
NG - Nigeria 6
SA - Arabia Saudita 6
VE - Venezuela 6
PY - Paraguay 5
SK - Slovacchia (Repubblica Slovacca) 5
AU - Australia 4
IQ - Iraq 4
PE - Perù 4
CO - Colombia 3
DZ - Algeria 3
EG - Egitto 3
LT - Lituania 3
BY - Bielorussia 2
CL - Cile 2
KG - Kirghizistan 2
NI - Nicaragua 2
PT - Portogallo 2
RO - Romania 2
TN - Tunisia 2
UY - Uruguay 2
ZW - Zimbabwe 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AL - Albania 1
AZ - Azerbaigian 1
BB - Barbados 1
BO - Bolivia 1
CD - Congo 1
CZ - Repubblica Ceca 1
EU - Europa 1
GE - Georgia 1
GN - Guinea 1
HR - Croazia 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
MA - Marocco 1
MK - Macedonia 1
MM - Myanmar 1
NO - Norvegia 1
OM - Oman 1
TT - Trinidad e Tobago 1
Totale 6.655
Città #
Singapore 576
Ashburn 270
Chandler 239
Santa Clara 175
Hong Kong 159
Fairfield 150
Hanoi 146
Southend 144
Hefei 143
Ho Chi Minh City 138
San Jose 110
Beijing 87
Seattle 79
Dublin 72
Houston 72
Princeton 72
Woodbridge 67
Boardman 66
Dong Ket 65
Seoul 65
Wilmington 60
Bern 55
Cambridge 52
Ann Arbor 49
Lauterbourg 48
Abidjan 46
Helsinki 45
Council Bluffs 42
Bologna 41
Los Angeles 40
Tokyo 33
Da Nang 30
Lomé 28
Berlin 25
Buffalo 23
Milan 23
Haiphong 22
New York 21
Dallas 20
Frankfurt am Main 20
Redondo Beach 20
Sofia 17
Westminster 15
Jakarta 14
Tianjin 14
Bengaluru 13
Brussels 13
Guangzhou 13
London 13
Shanghai 13
Johannesburg 12
Redwood City 12
Turin 12
Amman 11
Chicago 10
Des Moines 10
Nanjing 10
Biên Hòa 9
Olalla 9
Redmond 9
Falkenstein 8
Falls Church 8
Hải Dương 8
San Diego 8
São Paulo 8
Thái Bình 8
Yubileyny 8
Boston 7
Boydton 7
Florence 7
Montreal 7
Naples 7
Orem 7
Rome 7
Warsaw 7
Zhengzhou 7
Changsha 6
Denver 6
Glasgow 6
Hangzhou 6
Phoenix 6
Shenyang 6
Shenzhen 6
Thái Nguyên 6
Xi'an 6
Bühl 5
Bắc Ninh 5
Bến Tre 5
Cardiff 5
Forlì 5
Harbin 5
Jinan 5
Kyoto 5
Manila 5
Montescudo 5
Nha Trang 5
Padua 5
Quận Bình Thạnh 5
Shijiazhuang 5
Tashkent 5
Totale 4.115
Nome #
A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. 228
Circulating tumor cells in genitourinary tumors 213
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience 199
Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors 191
Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma. 184
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 165
Cabozantinib-related cardiotoxicity: a prospective analysis in a "real world" cohort of metastatic renal cell carcinoma patients 160
Glioblastoma: Emerging treatments and novel trial designs 157
Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases 157
Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis. 156
The clinical and prognostic role of ALK in glioblastoma 154
Immune checkpoint inhibitors for metastatic bladder cancer 153
New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes. 147
The human microbiota and prostate cancer: Friend or foe? 143
Diagnostic and Therapeutic Strategy in Anaplastic (Malignant) Meningioma, CNS WHO Grade 3 143
The Biological and Clinical Role of the Telomerase Reverse Transcriptase Gene in Glioblastoma: A Potential Therapeutic Target? 140
Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study 137
Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem 136
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 134
Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis 134
Immortal time bias question in the association between toxicity and outcome of immune checkpoint inhibitors 133
Distinct MRI pattern of "pseudoresponse" in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review 130
Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer? 125
Idh1 non-canonical mutations and survival in patients with glioma 124
IDH1105GGT single nucleotide polymorphism improves progression free survival in patients with IDH mutated grade II and III gliomas 122
A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. 121
Discovering the molecular landscape of meningioma: The struggle to find new therapeutic targets 121
Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. 118
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study 118
Expertise is crucial to prolong survival in average risk medulloblastoma: long-term results of a retrospective study 115
Meningioma: Not always a benign tumor. A review of advances in the treatment of meningiomas 115
Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma 111
Machine learning in neuro-oncology: toward novel development fields 110
Rare Primary Central Nervous System Tumors in Adults: An Overview 106
Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer 104
Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers 103
IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment 103
Optimizing renal function and outcome of patients with cT2 renal cell carcinoma 98
Re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.09.008 98
Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor 96
Radiomics, mirnomics, and radiomirRNomics in glioblastoma: defining tumor biology from shadow to light 96
How to predict progression-free survival in patients with grade 2 IDH-mutated diffuse gliomas after surgery: a long-term follow-up analysis 92
Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients 88
Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives. 86
Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: An unassessed issue 81
Molecular mechanisms related to hormone inhibition resistance in prostate cancer 73
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications 71
Targeting Mitochondria in Glioma: New Hopes for a Cure 65
Cabazitaxel in metastatic prostate cancer 62
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study 61
Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma 54
Immortal Time Bias Question in the Association Between Toxicity and Outcome of Immune Checkpoint Inhibitors 52
The role of the MET/AXL pathway as a new target for multikinase inhibitors in renal cell carcinoma 49
Gender- and Grade-Dependent Activation of Androgen Receptor Signaling in Adult-Type Diffuse Gliomas: Epigenetic Insights from a Retrospective Cohort Study 44
Adjuvant therapy in renal cell carcinoma-is pharmacogenomics assessment another element to select our patients? 43
Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back? 35
Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis 32
Immunophenotypic Profile of Adult Glioblastoma IDH-Wildtype Microenvironment: A Cohort Study 29
Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: an unassessed issue 26
New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes 25
N-Myc a key gene promoting a worst prostate cancer progression 24
Future perspectives for personalized immunotherapy in renal cell carcinoma 23
null 22
Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462–8 20
The role of adjuvant chemotherapy in patients with H3K27 altered diffuse midline gliomas: a multicentric retrospective study 19
Immunohistochemical Characterization of Tumor Microenvironment Analysis in Glioblastoma IDH-Wildtype 19
MGMT methylation as a prognostic factor in IDH wild type anaplastic gliomas 18
Pembrolizumab plus axitinib: A new treatment option for patients with metastatic renal cell carcinoma 16
Totale 6.827
Categoria #
all - tutte 21.715
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.715


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021176 0 0 0 0 0 0 0 0 0 14 7 155
2021/2022609 12 18 15 24 53 22 9 61 56 59 187 93
2022/2023974 90 106 42 100 64 120 28 67 181 37 52 87
2023/2024309 44 62 25 34 19 45 17 26 8 18 2 9
2024/20251.229 65 165 108 86 236 62 64 34 9 115 79 206
2025/20262.823 231 354 266 213 298 151 388 146 571 205 0 0
Totale 6.827